Synthesis of a DOTA--glyco bifunctional chelating agent and preliminary and study of [Ga]Ga-DOTA--glyco-RGD.
Fiche publication
Date publication
février 2021
Journal
RSC advances
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MARIE Pierre-Yves, Pr BOURA Cédric, Dr ROEDER Emilie
Tous les auteurs :
Mangin F, Collet C, Jouan-Hureaux V, Maskali F, Roeder E, Pierson J, Selmeczi K, Marie PY, Boura C, Pellegrini-Moïse N, Lamandé-Langle S
Lien Pubmed
Résumé
The design of bifunctional chelating agents (BFCA) allowing straightforward radiometal labelling of biomolecules is a current challenge. We report herein the development of a bifunctional chelating agent based on a DOTA chelator linked to a -glycosyl compound, taking advantage of the robustness and hydrophilicity of this type of carbohydrate derivative. This new BFCA was coupled with success by CuAAC with c(RGDfK) for αβ integrin targeting. As attested by evaluation, the conjugate DOTA--glyco-c(RGDfC) demonstrated high affinity for αβ integrins (IC of 42 nM). [Ga]Ga-DOTA--glyco-c(RGDfK) was radiosynthesized straightforwardly and showed high hydrophilic property (log = -3.71) and stability (>120 min). Preliminary PET study of U87MG engrafted mice gave evidence of an interesting tumor-to-non-target area ratio. All these data indicate that [Ga]Ga-DOTA--glyco-c(RGDfK) allows monitoring of αβ expression and could thus be used for cancer diagnosis. The DOTA--glycoside BFCA reported here could also be used with various ligands and chelating other (radio)metals opening a broad scope of applications in imaging modalities and therapy.
Référence
RSC Adv. 2021 Feb 10;11(13):7672-7681